/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Sigyn Therapeutics (SIGY) generated about n/a in revenue and -$3 million in net income over the trailing twelve months, growing at roughly 35.0% a year. Figures are from SEC filings; this is analysis, not investment advice.
Sigyn Therapeutics reported about -$3 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Sigyn Therapeutics's revenue has compounded at roughly 35.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside SIGY's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 14 Nov 2025, covering the period ending 30 Sept 2025, as reported to the SEC. Data last refreshed 9 Sept 2026. How this is calculated.
Fiscal year ends Dec.